134
Views
12
CrossRef citations to date
0
Altmetric
Review

Measuring and monitoring health-related quality of life responsiveness in systemic lupus erythematosus patients: current perspectives

Pages 339-343 | Published online: 04 Oct 2018

Abstract

Objective

Little is known about health-related quality of life (HRQoL) responsiveness in systemic lupus erythematosus (SLE) patients, compared to other chronic diseases. This review summarizes the available data in HRQoL responsiveness and sensitivity to change in SLE, and recommends directions for research and clinical application.

Methods

A review of the literature was conducted reporting on HRQoL responsiveness in adult SLE patients between 1984 and 2018. HRQoL studies were assessed for responsiveness, sensitivity of change, minimal important differences, minimal clinical important differences, or change in improvement or deterioration.

Results

Responsiveness or sensitivity to change in health-related status was observed in Medical Outcome Survey Short Form-36, SLE Symptom Checklist, EuroQoL, and Medical Outcomes Study Short Form 6D. SLE-specific quality of life questionnaire demonstrated greater responsiveness than the individual domains of SF-36. Lupus quality of life showed large responsiveness when there was improvement. LupusPRO and its derivative Lupus Impact Tracker were found to be responsive to change in disease activity, reflecting both improvement and worsening. Lupus Impact Tracker and physical health and pain domains of Lupus quality of life were responsive to SLE composite responder index.

Conclusion

This review highlights the need for further studies that capture responsiveness and change in HRQoL that are clinically meaningful and sustained. Most importantly, the choice of one measure over another is influenced by the purpose of the HRQoL measure, the particular HRQoL domain, and the SLE disease state that are relevant to the research question.

Introduction

Systemic lupus erythematosus (SLE) is a chronic multisystemic autoimmune disease associated with significant humanitarian burden and lower health-related quality of life (HRQoL).Citation1Citation5 To date there have been a number of reviews conducted to assess measures of HRQoL in SLE, mostly focusing on the developmental process and the psychometric properties.Citation6Citation8 Measuring responsiveness of generic and SLE-specific HRQoL questionnaires and the ability to capture a change in SLE-related health status remain underreported.

The aim of this review is to appraise studies that estimate the responsiveness to change in HRQoL status according to adult SLE patients’ concerns and determine the magnitude of change in the domain scores of these tools.

Methods

Search strategy: review of the literature

A review of English language publications limited to adult (age ≥18 years) SLE patients was performed from 1984 till January 2018. Search terms used were “quality of life and lupus”, “responsiveness”, “sensitivity of change”, minimally important difference (MID), or minimal clinical important difference (MCID). Inclusion criteria were manuscripts that reported HRQoL responsiveness or change of improvement or worsening. Exclusion criteria were abstracts, reviews, manuscripts that reported HRQoL in children or adolescents, or articles contained insufficient information on responsiveness or magnitude of change.

Results

The impact of change of generic and SLE-specific HRQoL measures used in SLE is described and depicted in .

Table 1 HRQoL measures used in SLE

Generic HRQoL measures used in SLE

Medical Outcome Survey Short Form-36 (MOS SF-36)

The SF-36 has been widely used successfully to assess HRQoL in SLE patients in many regions of the world. Therapeutic interventions in clinical trials had shown improvement in HRQoL using SF-36 allied with reduction in SLE disease activity including, prasterone,Citation9 mycophenolate mofetil,Citation10 abetimus sodium,Citation11 epratuzumab,Citation12 and belimumab.Citation13

Mild to moderate responsiveness of SF-36 is reported in SLE patients. Mean changes from baseline in the eight SF-36 domain scores, physical component summary (PCS) and mental component summary (MCS) scores, were generally in agreement with improved, unchanged, and worsened patient global assessment scores. Patients with improved or unchanged British Isles Lupus Activity Group score (BILAG) General and Musculoskeletal status compared to baseline experienced a statistically significant improvement in most SF-36 PCS scores with effect sizes (ES) in the range of 0.3–0.7. Scores remained stable for patients with worsened BILAG ratings compared to baseline with ES generally <0.3.Citation14

Using a patient-reported overall health status anchor, MID for SF-36 was reported at 2.1 (better) and −2.2 (worse) for the PCS and 2.4 (better) and −1.2 (worse) for the MCS.Citation15

The sensitivity to change of SF-36 was also compared to other SLE-specific HRQoL measures reflecting improvement and worsening overtime in patients with low and active disease state.Citation16Citation19 Using the anchor-based approach, the mean MID ranged from −2.0 for general health to −11.1 for role physical, and for improvement, the mean MID ranged from 2.8 for general health to 10.9 for bodily pain and vitality. Summary scores ranged from +2.5 to −0.8, and +5.0 to −2.5 for domain scores for improvement and deterioration, respectively.Citation18

Medical Outcomes Study Short Form 6D (SF-6D)

Evidence for the ability of SF-6D to detect change is mixed. SF-6D was found to be sensitive to self-reported improvement in health with small to medium ES, but insensitive to decline in health with a small to absent effects.Citation20

EuroQoL-5D (EQ-5D)

Similar to SF-6D, and SF-36, the sensitivity of the EQ-5D to improvement or decline in SLE disease activity index (SLEDAI) scores longitudinally was poor, with small to absent ES.Citation20 The EQ-5D measured significant improvement in HRQoL for patients self-reporting somewhat or much better health (mean EQ-5D change from 0.70 to 0.77) with small to medium ES. EQ-5D was insensitive to self-reported decline in health, showing small to absent effects. EQ-5D showed a trend towards improvement, with increased EQ-5D Visual Analog Scale (VAS) score during two visits, but not with decline.

Quality of Life Scale, Swedish version (QOLS-S)

No data on responsiveness is reported.

The National Institutes of Health Initiative Patient-Reported Outcomes Measurement Information System (PROMIS)

Limited responsiveness related to large ceiling effects is recognized, though patterns of worsening PROMIS-29 scores with increasing disease severity or declining health status were observed.Citation21 The 14 PROMIS Computer Adaptive Tests domains scores showed a weak and statically insignificant correlation with SELENA-SLEDAI and SLE damage index.Citation22

Disease-specific measures of HRQoL in SLE

Lupus Quality of Life (LupusQoL)

Responsiveness was assessed based on patient-reported global rating of change and physician-reported disease activity change scores in a longitudinal SLE study.Citation18 For disease activity, some LupusQoL domains showed responsiveness when there was improvement but none for deterioration. For deterioration, the mean LupusQoL change scores ranged from −2.5 for the body image domain to −7.7 for the intimate relationships domain. For improvement, the mean LupusQoL change scores ranged from 5.6 in the physical health domain to 10.4 in the burden to others domain. Using the anchor-based approach, the mean MID for LupusQoL ranged from −2.4 for body image to −8.7 for intimate relationship for deterioration, and 3.5 for body image to 7.3 for burden to others for improvement.

LupusQoL and SF-36 were measured using anchors for responsiveness defined by patients’ global assessment of disease impact according to changes in VAS.Citation16 Absence of symmetry in the responsiveness between worsening and improving patients was observed. Responsiveness varied among symptoms. The MID for global improvement ranged from 1.1 to 9.2 and from 1.9 to 11.3 for LupusQoL and SF-36 domain scores, respectively (excluding LupusQoL aggregated domains and SF-36 MCS/PCS). In worsening patients, the MID ranged from −0.5 to −6.4 in LupusQoL domains and from −4.4 to −15.6 in SF-36 domains.

LupusQoL and SF-36 were found to be responsive to SLE flares and improvement according to clinical anchors using SLEDAI-2K.Citation17 Both SF-36 and LupusQoL were responsive in patients with low disease activity state. No clear distinction was made in terms of standardized response mean (SRM) between the SF-36 and LupusQoL, but LupusQoL values were slightly better.

Both SF-36 and LupusQoL were found to be sensitive to change in SLE patients with active disease state and using different definitions of MCID, reflecting both improvement and worsening.Citation19 LupusQoL-specific domains (planning, burden to others, body image, and intimate relationship) were largely responsive to change.

Two domains of LupusQoL were found to be responsive to SLE Responder index (SRI). SRM and (ES) for physical health and pain domains were 0.42 (0.23) and 0.65 (0.44), respectively.Citation23

Systemic Lupus Erythematosus-Specific Quality-of-Life Questionnaire (SLEQOL)

SLEQOL demonstrated greater responsiveness than the individual domains of SF-36 in SLE.Citation24 MID was derived using a distributional approach in which SLEQOL scores were anchored to the patient global ratings of changes in their HRQoL. By taking the mean of the absolute difference of SLEQOL scores in the group of patients who rated their global HRQoL change as +2 to +3 (“moderately worse” or “a little worse”) and −2 to −3 (“moderately better” or “a little better”), the MID was calculated at 24.76. The Thai version of SLEQOL had moderate response to change in HRQoL with a SRM estimated at 0.50.Citation25

SLE Quality of Life Questionnaire (L-QoL)

No data on responsiveness is reported.

Systemic Lupus Erythematosus Symptom Checklist (SSC)

Responsiveness was investigated in patients with proliferative lupus nephritis at the beginning of treatment with cyclophosphamide and 1 year after.Citation26 Significant changes were observed in several symptoms related to the disease and total distress level. The Euro-Lupus group tended to show a higher HRQoL than the National Institute of Health group on 4 of 7 scales of the SF-36.

Systemic Lupus Erythematosus PRO (LupusPRO)

Most of LupusPRO domains were found to be responsive to changes against self-reported change in health status, physician global assessment, BILAG, SLEDAI, and Lupus Foundation-defined flare (SFI).Citation23 Body Image in Lupus Screen was found to be responsive to change in body image. Lupus Impact Tracker (LIT) was found to be responsive to changes in SELENA-SLEDAI, SFI, and SRI.Citation27 LIT mean scores decreased by more than 3 with improvement in physician global assessment (SRM −0.26), while it increased by more than 5 with worsening in SELENA-SLEDAI (SRM 0.42). Mean change in LIT of >±3 was noted with change in SFI status. Mean LIT score decreased by >4 and increased by >2 with patient-reported improvement and worsening in SLE health status respectively. LIT SRM (ES) among SRI responders and nonresponders were −0.69 (−0.36) and −0.20 (−0.12), respectively.

Conclusion

The SF-36, SF-6D, EQ-5D, LupusQoL, SLEQOL, and LupusPRO are the most used measures in SLE research. The larger ceiling effects observed in generic measures make them less sensitive to change in disease or treatment effect than SLE-specific questionnaires. Findings from this review support the use of both generic, such as PROMIS domains or SF-36, and specific SLE-related measures, such as LupusPRO, LupusQoL, SLEQOL, or LIT. Future research with well-defined samples of SLE subjects including, similar disease activity state (mild, severe, remission), specific organ involvement, therapeutic measures, and comorbid conditions, with appropriate statistical analyses and longitudinal design is needed.

Disclosure

The author reports no conflicts of interest in this work.

References

  • UrowitzMGladmanDDIbañezDChanges in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosusArthritis Care Res201466913741379
  • JollyMHow does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?J Rheumatol20053291706170816142864
  • PlantingaLLimSSBowlingCBDrenkardCAssociation of age with health-related quality of life in a cohort of patients with systemic lupus erythematosus: the Georgians Organized Against Lupus studyLupus Sci Med201631e00016127547440
  • FortinPRAbrahamowiczMNevilleCImpact of disease activity and cumulative damage on the health of lupus patientsLupus1998721011079541094
  • ThumbooJFongKYChanSPA prospective study of factors affecting quality of life in systemic lupus erythematosusJ Rheumatol20002761414142010852263
  • McelhoneKAbbottJTehLSA review of health related quality of life in systemic lupus erythematosusLupus2006151063364317120589
  • MahieuMYountSRamsey-GoldmanRPatient-Reported Outcomes in Systemic Lupus ErythematosusRheum Dis Clin North Am201642225326327133488
  • HollowayLHumphreyLHeronLPatient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performanceHealth Qual Life Outcomes20141211625048687
  • NordmarkGBengtssonCLarssonAEffects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosusAutoimmunity200538753154016373258
  • TseKCTangCSLioWILamMFChanTMQuality of life comparison between corticosteroid- and-mycofenolate mofetil and corticosteroid- and-oral cyclophosphamide in the treatment of severe lupus nephritisLupus200615637137916830884
  • StrandVCrawfordBImprovement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodiesExpert Rev Pharmacoecon Outcomes Res20055331732619807601
  • StrandVPetriMKalunianKEpratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006Rheumatology201453350251124273022
  • StrandVLevyRACerveraRImprovements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trialsAnn Rheum Dis2014738384423524886
  • StollTGordonCSeifertBConsistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosusJ Rheumatol1997248160816149263159
  • ColangeloKJPopeJEPeschkenCThe minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36J Rheumatol200936102231223719723907
  • DevilliersHAmouraZBesancenotJFResponsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLERheumatology201554594094925361539
  • ToumaZGladmanDDIbañezDUrowitzMBIs there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?J Rheumatol20113891898190521724700
  • McelhoneKAbbottJSuttonCSensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus ErythematosusArthritis Care Res2016681015051513
  • NantesSGStrandVSuJToumaZComparison of the Sensitivity to Change of the 36-Item Short Form Health Survey and the Lupus Quality of Life Measure Using Various Definitions of Minimum Clinically Important Differences in Patients With Active Systemic Lupus ErythematosusArthritis Care Res2018701125133
  • AggarwalRWilkeCTPickardASPsychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosusJ Rheumatol20093661209121619369452
  • KatzPPedroSMichaudKPerformance of the PROMIS 29-Item Profile in Rheumatoid Arthritis, Osteoarthritis, Fibromyalgia, and Systemic Lupus ErythematosusArthritis care & research2017691312132128029753
  • KasturiSSzymonifkaJBurketJCValidity and Reliability of Patient Reported Outcomes Measurement Information System Computerized Adaptive Tests in Systemic Lupus ErythematosusJ Rheumatol20174471024103128412708
  • DevilliersHBonithon-KoppCJollyMThe lupus impact tracker is responsive to changes in clinical activity measured by the systemic lupus erythematosus responder indexLupus201726439640227587460
  • LeongKPKongKOThongBYDevelopment and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL) Rheumatology (Oxford)2005441267127615797980
  • KasitanonNWangkaewSPuntanaSSukitawutWLeongKPLouthrenoo WTan Tock Seng Hospital Lupus Study GroupThe reliability, validity and responsiveness of the Thai version of Systemic Lupus Erythematosus Quality of Life (SLEQOL-TH) instrumentLupus201322328929623358871
  • DaleboudtGMBergerSPBroadbentEKapteinAAHealth-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritisPsychol Health Med201116439340421749237
  • GiangrecoDDevilliersHAnnapureddyNBlockJAJollyMLupus Impact Tracker is responsive to physician and patient assessed changes in systemic lupus erythematosusLupus201524141486149126162686